These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1483316)

  • 21. Fine specificities of natural regulatory T cells after IVIG therapy in patients with Kawasaki disease.
    Burns JC; Touma R; Song Y; Padilla RL; Tremoulet AH; Sidney J; Sette A; Franco A
    Autoimmunity; 2015 May; 48(3):181-8. PubMed ID: 25822882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of IgG therapy on lymphocyte subpopulations in the peripheral blood of Kuwaiti women experiencing recurrent pregnancy loss.
    Mahmoud F; Diejomaoh M; Omu A; Abul H; Haines D
    Gynecol Obstet Invest; 2004; 58(2):77-83. PubMed ID: 15114031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activin a suppresses peripheral CD8
    Wu Q; Weng R; Xu Y; Wang L; Huang Y; Yang J
    BMC Immunol; 2021 Feb; 22(1):17. PubMed ID: 33622252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Glucocorticoid plus Intravenous Immunoglobulin in Children with Immunoglobulin-Insensitive Kawasaki Disease.
    Ma Y; Zhang J; Fan R
    J Healthc Eng; 2022; 2022():9011259. PubMed ID: 35463656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunological abnormalities and endothelial cell injury in Kawasaki disease.
    Nonoyama S
    Acta Paediatr Jpn; 1991 Dec; 33(6):752-5. PubMed ID: 1801555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The B cell superantigen-like interaction of intravenous immunoglobin (IVIG) with Fab fragments of V(H) 3-23 and 3-30/3-30.5 germline gene origin cloned from a patient with Kawasaki disease is enhanced after IVIG therapy.
    Leucht S; Uttenreuther-Fischer MM; Gaedicke G; Fischer P
    Clin Immunol; 2001 Apr; 99(1):18-29. PubMed ID: 11286538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of intravenous immunoglobulin non-responders in Kawasaki disease.
    Hwang JY; Lee KY; Rhim JW; Youn YS; Oh JH; Han JW; Lee JS; Burgner D
    Arch Dis Child; 2011 Nov; 96(11):1088-90. PubMed ID: 20551193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Immunoglobulin therapy].
    Ogata S; Ishii M
    Nihon Rinsho; 2014 Sep; 72(9):1617-22. PubMed ID: 25518412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunoglobulin G values before treatment are correlated with the responsiveness to initial intravenous immunoglobulin therapy for Kawasaki disease.
    Yanagimoto K; Nomura Y; Masuda K; Hirabayashi M; Morita Y; Yoshishige M; Ueno K; Eguchi T; Kawano Y
    Int Arch Allergy Immunol; 2014; 164(2):83-8. PubMed ID: 24903098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Kawasaki disease using locally product intravenous immunoglobulin.
    Sangtawesin C; Kirawitaya T; Layangkool T; Nawasiri W; Vimolsarawong N
    J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S656-60. PubMed ID: 14700163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose intravenous immunoglobulin downregulates the activated levels of inflammatory indices except erythrocyte sedimentation rate in acute stage of Kawasaki Disease.
    Lee KY; Lee HS; Hong JH; Han JW; Lee JS; Whang KT
    J Trop Pediatr; 2005 Apr; 51(2):98-101. PubMed ID: 15677370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin.
    Leung DY
    Clin Exp Immunol; 1996 May; 104 Suppl 1():49-54. PubMed ID: 8625544
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanisms of immunoglobulin action: observations on Kawasaki syndrome and RSV prophylaxis.
    Meissner HC; Schlievert PM; Leung DY
    Immunol Rev; 1994 Jun; 139():109-23. PubMed ID: 7927408
    [No Abstract]   [Full Text] [Related]  

  • 34. Pro-inflammatory cytokines, lymphocyte subsets and intravenous immunoglobulin therapy in Guillain-Barré syndrome.
    Tekgül H; Kütükçüler N; Cağlayan S; Tütüncüoğlu S
    Turk J Pediatr; 1998; 40(3):357-63. PubMed ID: 9763899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease.
    Kuo HC; Liang CD; Wang CL; Yu HR; Hwang KP; Yang KD
    Acta Paediatr; 2010 Oct; 99(10):1578-83. PubMed ID: 20491705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Marker of T-cell activation is elevated in refractory Kawasaki disease.
    Suzuki H; Suenaga T; Takeuchi T; Shibuta S; Yoshikawa N
    Pediatr Int; 2010 Oct; 52(5):785-9. PubMed ID: 20487370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunoglobulin therapy in older infants and children.
    Fischer GW
    Infect Dis Clin North Am; 1992 Mar; 6(1):97-116. PubMed ID: 1578124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exogenous immunoglobulin downregulates T-cell receptor signaling and cytokine production.
    Tawfik DS; Cowan KR; Walsh AM; Hamilton WS; Goldman FD
    Pediatr Allergy Immunol; 2012 Feb; 23(1):88-95. PubMed ID: 21265884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset.
    Fukunishi M; Kikkawa M; Hamana K; Onodera T; Matsuzaki K; Matsumoto Y; Hara J
    J Pediatr; 2000 Aug; 137(2):172-6. PubMed ID: 10931407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance to intravenous immunoglobulin (IVIG) in Kawasaki disease: no influence of different IVIG lot utilisation.
    Pagnini I; Marino A; Simonini G; Cimaz R
    Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S170. PubMed ID: 22410254
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.